[Evaluation of antiretroviral treatment in HIV infected adult in the department of dermatological venereology of the Donka National Hospital].
If the use of highly active antiretroviral therapies (HAART) have largely improved survival, morbidity and quality of life of the people living with HIV in Northern and Southern countries, and particularly in Africa, many obstacles have slowed down their use. Thus the monitoring of patients under HAART in certain developing countries is still very low, if not non-existent. The objective of this study was to bring the therapeutic outcomes obtained after a minimal six months period of monitoring among HIV positive patients admitted in external consultations or following hospitalizations. We carried out a retrospective descriptive study concerning patients monitored from January 1st, 2004 to December 31st, 2008, that is to say 5 years. Our study consisted of 275 patients including 61.41% women with a man:woman sex-ratio of 0.62. The average age of our patients was of 36.83 [ranging from 18 to 70]. The initial average weight of our patients was 59.88 kg [range: 30-107] with the majority (66.91%) at stage III of the WHO clinical classification. The serologic profile was dominated by the HIV1 (97.09%) with a CD4 average of 210.99 cellules/mm3, the the start of the HAART. The evolution under treatment was marked clinically by an average ponderal gain of 7,45kg, with average weight going from 59.88 kg to 67.33 kg between M0 and M54. Biologically, the CD4 average went from 210.99 to 643 between M0 and M48 or an average gain of 432.01 cells/mm3. On the virological level, the plasmatic viral load carried out on 64 patients out of 275, was undetectable in 31 patients or 48.44% of cases. Our findings show that the therapeutic outcomes for patients under HAART was good and with a satisfactory clinical response, marked by an increase in the average weight which indicates a good immunological and virological response.